Comparing the current results to its competitors, Peak Bio Inc reported Revenue decrease in the 3 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.39 %, recorded in the same quarter.
Peak Bio Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical and pharmaceutical sectors, focusing on treatments for alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS). It competes with other biopharmaceutical companies, academic research institutions, governmental agencies, and various public and private research organizations. Currently, four alpha1-proteinase inhibitors for intravenous administration during AAT augmentation therapy are available in the U.S. market: Prolastin-C by Grifols, Aralast by Shire, Zemaira by CSL, and Glassia by Kamada. Kamada is also developing an inhaled form of augmentation therapy. Apic Bio and Adverum are in early stages of developing gene therapy approaches for AATD. Santhera has in-licensed an inhaled neutrophil elastase inhibitor (NEI) and plans a multiple ascending dose study targeting cystic fibrosis. Additionally, Alvelestat (MPH-966), developed through a partnership between Mereo Biopharma and AstraZeneca, has been investigated in a phase study. Competitors identified in company filings include Adverum, Apic Bio, AstraZeneca, CSL, Grifols, Kamada, Mereo Biopharma, Santhera, and Shire.
Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.
Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.
Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.
Sources:
Peak Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Peak Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
